Skip to main content
    Educational information only. This site does not provide medical advice. Read full disclaimer
    PepTracker Pro
    Open the App
    Research-only content. This page is for educational purposes and does not constitute medical advice. Read full disclaimer →

    AT7687

    Low Evidence

    A first-in-class GIPR antagonist peptide in early clinical development for obesity, designed as a once-weekly combination partner that adds weight loss and improves insulin sensitivity independent of appetite suppression.

    AliasesAntag GIPR antagonist+1 more
    EvidenceLow Evidence
    Last Updated 2026-05-30
    Reading Time 3 min

    What It Is

    AT7687 is a first-in-class glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist peptide developed by Antag Therapeutics, a Danish biotech, for the treatment of obesity. Unlike the GIPR-agonist arm of tirzepatide, AT7687 blocks the GIP receptor — a genetically validated pathway implicated in fat storage, insulin resistance, and metabolic dysfunction. On January 8, 2026, Antag reported topline data from two studies. A Phase 1 first-in-human study, conducted in both healthy volunteers and people living with obesity, showed AT7687 was well tolerated and suitable for once-weekly subcutaneous dosing with no need for titration. A preclinical study in obese, insulin-resistant, pre-diabetic non-human primates randomized animals to placebo, cagrilintide, AT7687, or the combination for 42 days; the AT7687 plus cagrilintide combination produced robust, sustained low-double-digit-percentage weight loss that did not plateau, with the additional weight loss in the combination group reported to be independent of appetite suppression. The combination also improved body composition and insulin sensitivity without increasing the tolerability burden. Earlier data demonstrated additive weight loss when AT7687 was paired with a GLP-1 agonist, positioning the molecule as a versatile combination partner rather than a standalone therapy. Antag announced in April 2026 that it will present AT7687 data at the American Diabetes Association 86th Scientific Sessions (June 5-8, 2026, New Orleans), placing the GIPR-antagonism approach among the closely watched next-generation obesity mechanisms.

    Also known as: Antag GIPR antagonist, AT-7687

    Regulatory Status

    Investigational

    Phase 1 first-in-human data reported January 2026. Not approved in any jurisdiction.

    Effective: 2026

    View FDA Source

    Why Researchers Study It

    AT7687 represents an emerging obesity drug class — GIPR antagonists — that takes the opposite pharmacological approach to the GIPR-agonist component of tirzepatide. Researchers study it because GIPR antagonism appears to add weight loss and improve insulin sensitivity and body composition through a mechanism independent of appetite suppression, making it an attractive combination partner for amylin agonists and GLP-1 agonists without compounding gastrointestinal tolerability burden.

    Proposed Mechanisms

    • Antagonizes (blocks) the GIP receptor, a pathway linked to fat storage and insulin resistance
    • Adds weight loss independent of central appetite suppression in preclinical models
    • Improves insulin sensitivity and body composition when combined with amylin or GLP-1 agonists
    • Long-acting design enables once-weekly subcutaneous dosing without titration

    Evidence Snapshot

    Low Evidence
    Low
    Medium
    High
    Study Type Model Outcome Link
    Human (Phase 1) First-in-human study in healthy volunteers and people with obesity Well tolerated; suitable for once-weekly subcutaneous dosing with no titration required Source
    Preclinical (non-human primate) Obese, insulin-resistant, pre-diabetic NHP; 42-day randomized study vs placebo, cagrilintide, AT7687, and combination AT7687 + cagrilintide produced robust, sustained low-double-digit % weight loss with no plateau; gains in insulin sensitivity and body composition independent of appetite suppression Source

    Commonly Discussed Benefits

    Researching AT7687? Track it, set reminders, and keep notes in the free app.

    Track in App

    Safety & Cautions

    • Only Phase 1 and preclinical data available; no Phase 2 efficacy in humans yet
    • Human weight-loss magnitude not established — combination weight loss reported in animals
    • Long-term safety and efficacy unknown
    • Available only through clinical trial enrollment
    • Not FDA-approved; not a compounding-eligible peptide

    Comparisons

    See how AT7687 compares to related peptides:

    Calculator Tools

    Use our research tools to explore dosing and reconstitution data:

    Citations

    1. [1] Antag Therapeutics — Phase 1 tolerability and amylin combination data (Jan 2026) PubMed
    2. [2] Antag Therapeutics — AT7687 to be presented at ADA 2026 Scientific Sessions (Apr 2026) PubMed
    3. [3] AT7687 + cagrilintide NHP weight loss and insulin sensitivity data PubMed

    Keep researching in the app

    • Log AT7687 to your private tracker
    • Set a dosing reminder
    • Compare it side-by-side with your stack

    Related Peptides

    Tirzepatide

    High Evidence

    A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.

    Cagrilintide

    High Evidence

    A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.

    Eloralintide

    Medium Evidence

    A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2.

    Maridebart Cafraglutide (MariTide)

    Medium Evidence

    Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1.